Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents

Pharmacotherapy

Volumn 22, Issue 1 I, 2002, Pages 54-65

  Ergul, A ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; 3 [2 (3,4 DIMETHOXYPHENYL)ETHOXY] 2 (4,6 DIMETHOXY 2 PYRIMIDINYLOXY) 3,3 DIPHENYLPROPIONIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; A 127772; A 182086; ATRASENTAN; BMS 193884; BMS 20794; BQ 162; BQ 610; CGS 27830; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO CYSTEIC ACID PROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; EMD 94246; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; IRL 3630; L 744453; L 749329; L 754142; LU 208075; LU 224332; LU 302146; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; TISSUE DISTRIBUTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; HUMANS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 0036140090     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.1.54.33505     Document Type: Review

References (101)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
3. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
4. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
5. Endothelin-1 promotes mitogenesis in airway smooth muscle cells
6. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes
7. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages
8. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes
9. Evidence of the endothelin-1 autocrine loop in cardiac myocytes: Relation to contractile function with congestive heart failure
10. Stimulatory effect of thrombin on endothelin-1 production in isolated glomeruli and cultured mesangial cells of rats
11. A membrane-bound metalloproteinase that catalyzes the proteolytic activation of big endothelin-1
12. Human endothelin converting enzyme (ECE-1): Three isoforms with distinct subcellular localizations
13. A fourth isoform of endothelin converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization
14. Isoforms of endothelin converting enzyme: Why and where?
15. Endothelin as a regulator of cardiovascular function in health and disease
16. Polar secretion of endothelin-1 by cultured endothelial cells
17. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch
18. Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium
19. Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells
20. Prolonged exercise causes an increase in endothelin-1 production in the heart in rats
21. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia
22. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
23. Effects of glucose and insulin on immunoreactive endothelin-1 release from cultured bovine endothelial cells
24. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta
25. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells
26. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression
27. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: Evidence for intracellular converting enzyme
28. Signal transduction pathways in cytokine stimulation endothelin-1 release from human vascular smooth muscle cells
29. Role of cyclic nucleotides in the regulation of endothelin-1 production by human endothelial cells
30. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression
31. Inhibitors of endothelin
32. Clearance of circulating endothelin-1 by ETB receptors in rats
33. Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo
34. Evidence for endothelin-induced renal vasoconstriction independent of endothelin A receptor activation
35. Threshold concentrations of endothelin-1 potentiates contractions to norepinephrine and serotonin in human arteries
36. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
37. Endothelins in the normal and diseased kidney
38. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice
39. Stimulation of interleukin-6 production by endothelin in rat bone marrow-derived stromal cells
40. Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 by human brain-derived endothelial cells
41. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells
42. Endothelin-induced collagen remodeling in experimental pulmonary hypertension
43. Endothelin stimulates human polymorphonuclear leukocytes (PMN) adhesion to endothelial cells: Regulation by cGMP
44. In vitro effect of endothelin-1 on collagen, and ADP-induced aggregation in human whole blood and platelet rich plasma
45. Endothelial dysfunction and hypertension
46. A rationale for treatment of endothelial dysfunction in hypertension
47. Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11 beta hydroxysterol dehydrogenase inhibition: Role of nitric oxide
48. Role of endothelin in the increased vascular tone of patients with essential hypertension
49. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats
50. Role of endothelin-1 in hypertension
51. Role of endothelin-1 in hypertension and vascular disease
52. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats
53. Plasma immunoreactive endothelin in essential hypertension
54. The endothelin system and its potential as a therapeutic target in cardiovascular disease
55. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension
56. The effect of regulation of high blood pressure on plasma endothelin-1 levels in African-American hypertensives
57. Regulation of plasma endothelin by salt in salt-sensitive hypertension
58. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males
59. Urinary excretion of vasoactive factors are correlated to sodium excretion
60. Distribution of endothelin receptors in saphenous veins of African Americans: Implications of racial differences
61. Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist
62. Localization of sites of enhanced expression of endothelin-1 in the kidney of deoxycorticosterone acetate-salt hypertensive rats
63. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats: Comparison with angiotensin converting enzyme inhibition and calcium antagonism
64. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension
65. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
66. Endothelin in human congestive heart failure
67. Plasma endothelin in chronic heart failure
68. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?
69. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
70. ET-1 in myocardial interstitium in heart failure: Relation to myocyte ECE activity and expression
71. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
72. Concomitant endothelin receptor subtype-A blockade during progression of pacing-induced congestive heart failure in rabbits
73. Endothelin stimulates multiple responses in isolated adult ventricular myocytes
74. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure
75. Endothelin in chronic heart failure: Current position and future prospects
76. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETa receptor blockade in chronic heart failure patients treated with ACE inhibitors
77. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload
78. Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure
79. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
80. Multicenter, doubleblind, placebo-controlled study of long-term endothelin blockade with bosentan in clinical heart failure - Results of REACH-1 trial
81. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III and IV congestive heart failure
82. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure
83. Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure
84. Improved hemodynamics with the ET(A) selective receptor antagonist BM5-193884 in patients with heart failure
85. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
86. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina
87. Increased plasma endothelin-1 in the early hours of acute myocardial infarction
88. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
89. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol
90. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure
91. Inhibition of myocardial endothelin pathway improves long term survival in heart failure
92. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat
93. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
94. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
95. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects; evidence for increased production of endothelin in pulmonary circulation
96. Human pulmonary circulation is an important site for both clearance and production of ET-1
97. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction
98. The endothelin receptor antagonist bosentan prevents short term hypoxia induced pulmonary hypertension in the rat
99. Contribution of endogenous endothelin-1 to the progression of cardio-pulmonary alterations in rats with monocrotaline-induced pulmonary hypertension
100. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
101. Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular function